A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)
Phase 1
- Conditions
- Obesity, Overweight, Overweight or ObesityTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2022-502839-19-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
Have obesity or overweight, If overweight, must also have one of the following: High blood pressure, high cholesterol, obstructive sleep apnea or heart disease., Have at least 1 self-report of an unsuccessful at dietary effort to lose weight
Exclusion Criteria
Have Type 1 diabetes, Type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma, Have a self-reported change in body weight >5 kg (11 pounds) within 90 days prior to screening., Have family (first-degree relative) or personal history of MTC or MEN2 syndrome, Have had a history of chronic or acute pancreatitis
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method